“On June 29, 2016, the U.S. Food and Drug Administration approved Kovanaze, a needleless, intranasally administered spray combination of the ester anesthetic tetracaine HCl plus the vasoconstrictor oxymetazoline HCl for regional maxillary anesthesia. Kovanaze is indicated for regional pulpal anesthesia when performing a restorative procedure on teeth 4 through 13 and A through J in adults and children who weigh 88 lbs or more. The drug is supplied as a prefilled, single-use sprayer that deliver 6 mg tetracaine HCl and 0.1 mg oxymetazoline HCl in each 0.2 mL spray.
Kovanaze should be administered intranasally ipsilateral (on the same side) to the maxillary tooth on which the dental procedure will be performed.
Contraindications to Kovanaze include: known hypersensitivity to tetracaine, benzyl alcohol, other ester local anesthetics, p-aminobenzoic acid (PABA), oxymetazoline, or any other component of the product. The most common adverse reactions occurring in 10% or more of patients include rhinorrhea, nasal congestion, lacrimation increased, nasal discomfort, and oropharyngeal pain. Transient, asymptomatic elevations in systolic blood pressure and diastolic blood pressures have been reported.”
Source: American Dental Association
Read more about this topic here: http://www.ada.org/en/science-research/science-in-the-news/new-intransally-administered-needleless-dental-anesthetic-approved-by-the-us-fda